News|Articles|July 1, 2025

Q2 2025 Recap: Hematology News and Updates

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

Hematology has been relatively silent compared to other fields in recent months, with few new treatments developed and fewer approvals from the US Food and Drug Administration (FDA). The majority of conditions, despite still being prevalent, are relatively well-handled.